Vebreltinib
- Generic Name
- Vebreltinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15F3N8
- CAS Number
- 1440964-89-5
- Unique Ingredient Identifier
- 2WZP8A9VFN
- Indication
用于治疗具有间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 31
- Registration Number
- NCT06644313
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Avistone Biotechnology Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06574347
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Avistone Biotechnology Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06343064
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath